Charles Schwab’s BioTelemetry, Inc. BEAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-225,272
Closed -$16.2M 3560
2020
Q4
$16.2M Buy
225,272
+1,987
+0.9% +$104K 0.01% 1553
2020
Q3
$10.2M Sell
223,285
-2,469
-1% -$103K ﹤0.01% 1686
2020
Q2
$10.2M Buy
225,754
+12,901
+6% +$578K 0.01% 1640
2020
Q1
$8.2M Buy
212,853
+3,730
+2% +$172K ﹤0.01% 1572
2019
Q4
$9.68M Buy
209,123
+7,457
+4% +$323K 0.01% 1684
2019
Q3
$8.21M Buy
201,666
+5,991
+3% +$259K ﹤0.01% 1716
2019
Q2
$9.42M Buy
195,675
+5,048
+3% +$265K 0.01% 1625
2019
Q1
$11.9M Buy
190,627
+8,867
+5% +$609K 0.01% 1471
2018
Q4
$10.9M Buy
181,760
+2,358
+1% +$142K 0.01% 1404
2018
Q3
$11.6M Buy
179,402
+16,154
+10% +$901K 0.01% 1545
2018
Q2
$7.35M Buy
163,248
+15,139
+10% +$604K 0.01% 1794
2018
Q1
$4.6M Buy
148,109
+7,475
+5% +$246K ﹤0.01% 1991
2017
Q4
$4.21M Buy
140,634
+13,962
+11% +$404K ﹤0.01% 2013
2017
Q3
$4.18M Buy
126,672
+14,238
+13% +$493K ﹤0.01% 1967
2017
Q2
$3.76M Sell
112,434
-13,336
-11% -$398K ﹤0.01% 1958
2017
Q1
$3.64M Buy
125,770
+7,140
+6% +$177K ﹤0.01% 1940
2016
Q4
$2.65M Buy
118,630
+13,771
+13% +$269K ﹤0.01% 2051
2016
Q3
$1.95M Buy
104,859
+66,159
+171% +$1.25M ﹤0.01% 2140
2016
Q2
$631K Hold
38,700
﹤0.01% 2511
2016
Q1
$453K Hold
38,700
﹤0.01% 2616
2015
Q4
$453K Hold
38,700
﹤0.01% 2688
2015
Q3
$474K Hold
38,700
﹤0.01% 2645
2015
Q2
$365K Hold
38,700
﹤0.01% 2796
2015
Q1
$343K Hold
38,700
﹤0.01% 2784
2014
Q4
$389K Hold
38,700
﹤0.01% 2732
2014
Q3
$260K Hold
38,700
﹤0.01% 2865
2014
Q2
$278K Buy
+38,700
New +$308K ﹤0.01% 2889

Other funds holding BEAT

Charles Schwab's BEAT Position: Q1 2021 in Review

Charles Schwab sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 225,272 shares — an estimated $16.2M sold.

Charles Schwab first reported a position in BEAT in Q2 2014 and held it in 27 quarters. The position peaked at $16.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • Charles Schwab reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • Charles Schwab sold 225,272 BioTelemetry, Inc. shares in Q1 2021, an estimated $16.2M.
  • Charles Schwab first reported a position in BioTelemetry, Inc. in Q2 2014 and held it in 27 quarters.
  • Charles Schwab's BioTelemetry, Inc. position peaked at $16.2M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.